Active Ingredient(s): Asciminib Hydrochloride
FDA Approved: * October 29, 2021
Pharm Company: * NOVARTIS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Scemblix Overview

Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).[1][2][3] Asciminib is a protein kinase inhibitor.[1] The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.[2] Asciminib was approved for medical use in the United States in October 2021.&a...

Read more Scemblix Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Scemblix Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Asciminib Hydrochloride
  • Tablet: 20mg, 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Scemblix: (2 results)

Sorted by National Drug Code
  • 0078-1091 Scemblix 20 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
  • 0078-1098 Scemblix 40 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Other drugs which contain Asciminib Hydrochloride or a similar ingredient: (1 result)